PPMD President Pat Furlong and Vice President of Research Sharon Hesterlee are attending MDA’s Scientific Conference this week in Washington, D.C. Most of what was presented are results that were previously announced. However, there were some interesting presentations, as well as, results worth repeating, that we wanted to share. Sharon and Pat will continue to blog from the conference:
From Pat Furlong
Interview with Thomas Voit
While the content…
ContinueAdded by PPMD on April 24, 2013 at 10:00am — 6 Comments
Below is the latest update PPMD has received from Dr. Rohit Batta, Global Medical Affairs and Patient Relations Leader in GSK's Rare Disease Unit :
ContinueThe purpose of this communication is provide an update to you, as you have requested, on GSK’s plans for providing the option of continued access to drisapersen for boys completing the US Ph IIb 48 week study (DMD114876)…
Added by PPMD on April 24, 2013 at 9:30am — No Comments
Guest post by Gail D. McVicker, Grandmother of Jake (10) and Ryan (6) - Pennsylvania
Duchenne: An Intergenerational Issue
Five years ago, I did not know the world of Duchenne muscular dystrophy existed. Before my young grandsons were officially diagnosed in 2008, my daughter told me that some genetic…
ContinueAdded by PPMD on April 17, 2013 at 2:49pm — 2 Comments
PPMD received the email update below from Hans Schikan at Prosensa:
Dear all,
Today, at the Cold Spring Harbor conference in the US, Dr John Kraus of GSK gave an excellent presentation on the outcome of the 117 (DEMAND II) clinical trial. The primary endpoint in this exploratory study was met and a statistically and clinically meaningful difference of 35 meters in the six-minute walk test between the continuous dosing regimen of 6mg/kg per week and placebo was…
ContinueAdded by PPMD on April 12, 2013 at 11:39am — No Comments
Below is the latest update PPMD has received from Dr. Rohit Batta, Global Medical Affairs and Patient Relations Leader in GSK's Rare Disease Unit :
ContinueTo keep you updated on the progress of the drisapersen (previously GSK2402968) clinical development program, as you have requested, I am writing to inform you that the results of the GSK Phase IIb study investigating drisapersen as…
Added by PPMD on April 5, 2013 at 10:51am — No Comments
Guest post by Ivy Scherbarth. Ivy is a Colorado/Wyoming FACES Coordinator for PPMD. Follow Ivy at her blog, Living Duchenne.
One interesting thing about silence is listening to…
ContinueAdded by PPMD on April 4, 2013 at 11:30pm — No Comments
2018
2017
2016
2015
2014
2013
2012
2011
2010
© 2021 Created by PPMD.
Powered by
Badges | Report an Issue | Privacy Policy | Terms of Service